Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis

被引:308
作者
deFilippi, C
Wasserman, S
Rosanio, S
Tiblier, E
Sperger, H
Tocchi, M
Christenson, R
Uretsky, B
Smiley, M
Gold, J
Muniz, H
Badalamenti, J
Herzog, C
Henrich, W
机构
[1] Univ Maryland, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[3] San Raffaele Univ Hosp, Dept Cardiol, Milan, Italy
[4] Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA
[5] Renal Care Grp, Angleton, TX USA
[6] Renal Specialists, Houston, TX USA
[7] Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55455 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 03期
关键词
D O I
10.1001/jama.290.3.353
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Context Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (less than or equal to40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n=67; 0%, 25%, 50%, and 62% prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 36 条
[1]
Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]
Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CIRCULATION, 2002, 106 (23) :2941-2945
[3]
End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].
Arici, M ;
Walls, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414
[4]
VALUE OF ECHOCARDIOGRAPHIC MEASUREMENT OF LEFT-VENTRICULAR MASS IN PREDICTING CARDIOVASCULAR MORBID EVENTS IN HYPERTENSIVE MEN [J].
CASALE, PN ;
DEVEREUX, RB ;
MILNER, M ;
ZULLO, G ;
HARSHFIELD, GA ;
PICKERING, TG ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) :173-178
[5]
Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: Angiographic correlates and long-term clinical outcomes [J].
deFilippi, CR ;
Tocchi, P ;
Parmar, RJ ;
Rosanio, S ;
Abreo, G ;
Potter, MA ;
Runge, MS ;
Uretsky, BF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (07) :1827-1834
[6]
DEPNER TA, 1999, PRINCIPLES PRACTICE, P97
[7]
Cardiac troponin T predicts mortality in patients with end-stage renal disease [J].
Dierkes, J ;
Domröse, U ;
Westphal, S ;
Ambrosch, A ;
Bosselmann, HP ;
Neumann, KH ;
Luley, C .
CIRCULATION, 2000, 102 (16) :1964-1969
[8]
CORONARY PLAQUE DISRUPTION [J].
FALK, E ;
SHAH, PK ;
FUSTER, V .
CIRCULATION, 1995, 92 (03) :657-671
[9]
A standardized definition of ischemic cardiomyopathy for use in clinical research [J].
Felker, GM ;
Shaw, LK ;
O'Connor, CM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :210-218
[10]
CLINICAL AND ECHOCARDIOGRAPHIC DISEASE IN PATIENTS STARTING END-STAGE RENAL-DISEASE THERAPY [J].
FOLEY, RN ;
PARFREY, PS ;
HARNETT, JD ;
KENT, GM ;
MARTIN, CJ ;
MURRAY, DC ;
BARRE, PE .
KIDNEY INTERNATIONAL, 1995, 47 (01) :186-192